Author:
Richie Thomas L.,Hoffman Stephen L.
Reference42 articles.
1. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, Wasserman GF, Reeve P, Diggs CL, Chulay JD. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987;1:1277–81.
2. Bastiaens GJ, Van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, Van Grinsven T, Sim BK, Billingsley PF, James ER, Gunasekera A, Bijker EM, Van Gemert GJ, Van De Vegte-Bolmer M, Graumans W, Hermsen CC, De Mast Q, Van Der Ven AJ, Hoffman SL, Sauerwein RW. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg. 2016;94:663–73.
3. Beaudoin RL, Strome CPA, Mitchell F, Tubergen TA. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol. 1977;42:1–5.
4. Clyde DF, Most H, Mccarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci. 1973;266:169–77.
5. Diawara H. ‘Pre-conception PfSPZ vaccine: safety and efficacy during subsequent pregnancy in Ouélessébougou, Mali’ annual meeting of the American Society of Tropical Medicine and Hygiene. Oral presentation Wednesday, November 2, 2022. 2022.